CMA 676: Phase II/III

The initial 59 patients treated in CTP's pivotal Phase II/III trial had a 36 percent remission rate and complete clearance of clinically evident leukemic cells. Data were presented at the American Society of Clinical Oncology meeting in Atlanta. ...